Topics

Maribavir safety and efficacy for cytomegalovirus infections among transplant recipients

09:11 EDT 11 Oct 2019 | 2 Minute Medicine

1. This phase 2, parallel-group randomized control trial compared the safety and efficacy profile of maribavir versus valgancicvlovir among patients who received solid organ transplants, finding that both medications had comparable efficacy profiles in preventing CMV infection within 6 weeks of starting therapy. 2. Patients randomized to receive maribavir had a higher incidence of adverse […]
Source: 2 Minute Medicine

Original Article: Maribavir safety and efficacy for cytomegalovirus infections among transplant recipients

NEXT ARTICLE

More From BioPortfolio on "Maribavir safety and efficacy for cytomegalovirus infections among transplant recipients"

Quick Search

Relevant Topic

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...